Pharmacodynamics of piperacillin/tazobactam against : antibacterial effect and risk of emergence of resistance.
作者信息
Carson Amy A, Bowker Karen E, Attwood Marie, Noel Alan R, MacGowan Alasdair P
机构信息
Infection Sciences, Pathology Quarter, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK.
Bristol Centre for Antimicrobial Research & Evaluation (BCARE), Severn Infection Sciences, Pathology Quarter, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK.
出版信息
JAC Antimicrob Resist. 2024 Jul 12;6(4):dlae108. doi: 10.1093/jacamr/dlae108. eCollection 2024 Aug.
Abstract
摘要
相似文献
1
Pharmacodynamics of piperacillin/tazobactam against : antibacterial effect and risk of emergence of resistance.哌拉西林/他唑巴坦的药效学：抗菌作用及耐药性产生风险
JAC Antimicrob Resist. 2024 Jul 12;6(4):dlae108. doi: 10.1093/jacamr/dlae108. eCollection 2024 Aug.
2
Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.β-内酰胺酶抑制剂与广谱青霉素的联合制剂：影响对肠杆菌科细菌和铜绿假单胞菌抗菌活性的因素
Pharmacotherapy. 2000 Sep;20(9 Pt 2):213S-218S; discussion 224S-228S. doi: 10.1592/phco.20.14.213s.35045.
3
In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.哌拉西林、哌拉西林-他唑巴坦和环丙沙星单独及联合应用对金黄色葡萄球菌、肺炎克雷伯菌、阴沟肠杆菌和铜绿假单胞菌的体外药效学。
Antimicrob Agents Chemother. 1995 Aug;39(8):1711-6. doi: 10.1128/AAC.39.8.1711.
4
Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.哌拉西林/他唑巴坦持续输注和间歇给药时的药代动力学和药效学
Clin Ther. 2002 Jul;24(7):1090-104. doi: 10.1016/s0149-2918(02)80021-2.
5
activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non- and collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018-2020.对来自西欧血流感染、腹腔内感染和尿路感染患者的哌拉西林/他唑巴坦耐药和/或美罗培南耐药的非肠杆菌科细菌和肠杆菌科细菌的活性：SMART 2018-2020。
J Med Microbiol. 2023 Feb;72(2). doi: 10.1099/jmm.0.001645.
6
Piperacillin/Tazobactam Dose Optimization in the Setting of Piperacillin/Tazobactam-susceptible, Carbapenem-resistant Pseudomonas aeruginosa: Time to Reconsider Susceptible Dose Dependent.哌拉西林/他唑巴坦敏感、碳青霉烯类耐药铜绿假单胞菌时的哌拉西林/他唑巴坦剂量优化：是时候重新考虑敏感剂量依赖性了。
Clin Ther. 2023 Jan;45(1):72-77. doi: 10.1016/j.clinthera.2022.12.004. Epub 2022 Dec 31.
7
Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam.铜绿假单胞菌对碳青霉烯类和哌拉西林/他唑巴坦的耐药模式。
J Chemother. 1999 Apr;11(2):93-6. doi: 10.1179/joc.1999.11.2.93.
8
Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients.住院患者中对哌拉西林-他唑巴坦耐药的铜绿假单胞菌的危险因素。
Antimicrob Agents Chemother. 2002 Mar;46(3):854-8. doi: 10.1128/AAC.46.3.854-858.2002.
9
Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD).整合药代动力学、药效学和 MIC 分布，以评估加拿大医院感染的铜绿假单胞菌临床分离株对抗菌药物活性的变化（CANWARD）。
J Antimicrob Chemother. 2013 May;68 Suppl 1:i67-72. doi: 10.1093/jac/dkt028.
10
Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin.克拉维酸在生理相关浓度下可诱导铜绿假单胞菌AmpC头孢菌素酶的表达，并拮抗替卡西林的抗菌活性。
Antimicrob Agents Chemother. 1999 Apr;43(4):882-9. doi: 10.1128/AAC.43.4.882.
本文引用的文献
1
Beta-Lactams Toxicity in the Intensive Care Unit: An Underestimated Collateral Damage?重症监护病房中的β-内酰胺类药物毒性：一种被低估的附带损害？
Microorganisms. 2021 Jul 14;9(7):1505. doi: 10.3390/microorganisms9071505.
2
Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?为重症患者设定β-内酰胺类药物治疗范围：是否存在下限甚至上限？
Crit Care Explor. 2021 Jun 11;3(6):e0446. doi: 10.1097/CCE.0000000000000446. eCollection 2021 Jun.
3
Clinical and pharmacokinetic/dynamic outcomes of prolonged infusions of beta-lactam antimicrobials: An overview of systematic reviews.β-内酰胺类抗菌药物延长输注的临床和药代动力学/药效学结局：系统评价概述。
PLoS One. 2021 Jan 22;16(1):e0244966. doi: 10.1371/journal.pone.0244966. eCollection 2021.
4
Comparing clinical outcomes of piperacillin-tazobactam administration and dosage strategies in critically ill adult patients: a systematic review and meta-analysis.比较哌拉西林他唑巴坦在危重症成年患者中的给药和剂量策略的临床结局：系统评价和荟萃分析。
BMC Infect Dis. 2020 Jun 20;20(1):430. doi: 10.1186/s12879-020-05149-6.
5
A survey of antibiotic administration practices involving patients with sepsis in UK critical care units.英国重症监护病房脓毒症患者抗生素使用情况调查。
Int J Clin Pharm. 2020 Feb;42(1):65-71. doi: 10.1007/s11096-019-00938-9. Epub 2019 Nov 14.
6
Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study.头孢他啶、碳青霉烯类或哌拉西林他唑巴坦作为铜绿假单胞菌菌血症的单一确定性治疗：一项多中心回顾性研究。
Clin Infect Dis. 2020 May 23;70(11):2270-2280. doi: 10.1093/cid/ciz668.
7
Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR).β-内酰胺类抗生素在危重症患者中的治疗优化：法国药理学和治疗学学会（Société Française de Pharmacologie et Thérapeutique-SFPT）和法国麻醉与重症监护医学学会（Société Française d'Anesthésie et Réanimation-SFAR）的指南。
Crit Care. 2019 Mar 29;23(1):104. doi: 10.1186/s13054-019-2378-9.
8
Optimisation of antimicrobial dosing based on pharmacokinetic and pharmacodynamic principles.基于药代动力学和药效学原理优化抗菌药物给药剂量。
Indian J Med Microbiol. 2017 Jul-Sep;35(3):340-346. doi: 10.4103/ijmm.IJMM_17_278.
9
DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?DALI 研究：确定重症监护病房患者的抗生素水平：目前的β-内酰胺类抗生素剂量是否足以满足重症患者的需求？
Clin Infect Dis. 2014 Apr;58(8):1072-83. doi: 10.1093/cid/ciu027. Epub 2014 Jan 14.
10
Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists.抗菌药物动力学概念在临床实践中的应用：聚焦β-内酰胺类抗生素：来自传染病药师协会的见解
Pharmacotherapy. 2006 Sep;26(9):1320-32. doi: 10.1592/phco.26.9.1320.
Zotero 插件